Research Blog
Thymic Peptides Explained: Thymalin vs. Thymosin Alpha-1 vs. Thymosin Beta-4 (TB-500)
Published
Thymalin, Thymosin Alpha-1, and TB-500 are often lumped together as immune peptides, but they differ in structure, evidence quality, and regulatory status. A research-first comparison.
For laboratory research use only. This article compares three thymus-associated peptides as they appear in the published literature, provided for reference. It is not medical, veterinary, or dosing guidance and makes no health, therapeutic, or outcome claims. Nothing described here is for human or animal use.
Thymic peptides are a broad category of compounds derived from, modelled on, or associated with thymus biology. They are frequently grouped together as “immune peptides”, but Thymalin, Thymosin Alpha-1, and Thymosin Beta-4 / TB-500 are not interchangeable. They differ in structure, in regulatory status, in the depth of their evidence base, and in the kind of question each has actually been studied to answer.
What each peptide is
Thymalin
A polypeptide complex originally isolated from thymus tissue, most commonly described as a calf-thymus-derived preparation. Its literature concerns immune regulation, immune ageing (immunosenescence), and contexts where thymus function or T-cell activity is the endpoint. That literature is largely older, region-specific, or mechanistic rather than trial-based.
Thymosin Alpha-1 (thymalfasin)
A defined 28-amino-acid peptide first associated with thymosin-fraction research. It has the largest clinical footprint of the three, with studies in chronic hepatitis B, hepatitis C, sepsis, oncology adjunct settings, and immune dysfunction. FDA briefing materials describe it as immunomodulatory, with reported activity linked to toll-like receptors, dendritic cells, lymphoid progenitor cells, NK cells, and Th1-related cytokines.
Thymosin Beta-4 and TB-500
Thymosin Beta-4 is a naturally occurring 43-amino-acid peptide involved in actin dynamics, cell migration, inflammation, angiogenesis, and tissue-repair biology. TB-500 is commonly described as a synthetic fragment corresponding to the actin-binding region of Thymosin Beta-4 — not the same molecule. FDA materials state that TB-500 contains amino acids 17–23 of full-length Thymosin Beta-4 and that human exposure data for TB-500 are lacking. Our breakdown of the TB-500 literature by model system follows that distinction through each body of evidence.
Described mechanisms
- Thymalin — reported influence on immune-cell differentiation, thymus-related signalling, and immune homeostasis.
- Thymosin Alpha-1 — reported modulation of T-cell maturation, Th1 cytokine signalling, dendritic-cell activity, and NK-cell function.
- Thymosin Beta-4 / TB-500 — actin binding, cell movement, wound-healing pathways, angiogenesis, and inflammation.
Evidence quality
Thymosin Alpha-1 carries the most human clinical research of the three, including randomised controlled studies in chronic hepatitis B and systematic reviews in sepsis, though study quality varies by indication. Thymalin has a more limited and less globally standardised evidence base, much of it from regional or older clinical traditions. TB-500 has the weakest human evidence profile of the three: FDA materials note no identified clinical studies or human exposure data for TB-500 by any route.
Side-by-side comparison
| Thymalin | Thymosin Alpha-1 | TB-500 | |
|---|---|---|---|
| Best described as | Thymus-derived peptide complex | Defined immune-modulating peptide | Synthetic Tβ4-related fragment |
| Primary research focus | Immune regulation, immunosenescence | Infectious disease, sepsis, oncology adjunct | Wound healing, tissue repair |
| Evidence strength | Preliminary to moderate | Strongest of the three, indication-specific | Largely preclinical / investigational |
| Key caution in the literature | Preparation standardisation, few modern trials | Immune-activation profile is indication-dependent | Human safety profile uncharacterised; anti-doping restrictions |
Regulatory notes reported by FDA and WADA
FDA materials on compounded Thymosin Alpha-1 and TB-500 identify immunogenicity, aggregation, peptide impurities, and inadequate safety information as concerns — which is a statement about the quality and characterisation of the material itself, and a direct argument for working only from independently verified material. The 2026 WADA Prohibited List names Thymosin-β4 and derivatives such as TB-500 under growth factors and growth factor modulators, prohibited at all times.
Verifying the material you are actually studying
Because “thymic peptide” covers three structurally unrelated things, identity confirmation matters more here than almost anywhere else in the catalogue: a mass-spectrometry identity trace and an HPLC purity trace tell you which molecule is in the vial. TB-500 appears in research blends such as BPC + TB500 and the GHK-Cu-containing KLOW 80mg, both third-party tested with published certificates. Our COA archive holds those records and how to read an HPLC chromatogram covers what the trace is telling you.
Bottom line
Of the three, Thymosin Alpha-1 is the most clinically studied; Thymalin is best read as a thymus-derived immunoregulatory preparation with a less standardised evidence base; and TB-500 remains a tissue-repair research compound with substantial human-data and regulatory uncertainty. Grouping them as one category is the error the literature does not support.
For laboratory and research use only. Not for human consumption. Nothing here is intended for human or animal use. All materials referenced are supplied strictly for in-vitro and other controlled preclinical research by qualified professionals and are third-party tested for identity and purity.